{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T12:28:57Z","timestamp":1765974537938,"version":"3.48.0"},"reference-count":34,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Predicting treatment persistence in inflammatory bowel disease (IBD) remains challenging despite a broadened therapeutic arsenal. This study used longitudinal data to assess drug persistence across four biologics for IBD prior to Interleukin (IL)-23 blocker approval. Methods: We retrospectively analyzed IBD outpatients at Goethe University Hospital. Laboratory data and treatment adherence were collected to determine how many patients continued each biological therapy after induction and at 1 year. Results: Of 587 patients, those on azathioprine or mercaptopurine were excluded (focusing on biologics). Four biologicals were analyzed: 280 patients received one of them; 312 (53.2%) had Crohn\u2019s disease and 275 (46.8%) had Ulcerative Colitis. Infliximab (IFX) was given to 93 patients (median 912 days; range 20\u20135273); at endpoint, 39 (42.4%) remained on IFX. Adalimumab (ADA) was used by 165 patients (median 1051 days; range 48\u20134458); 87 (52.4%) remained at endpoint. Vedolizumab (VDZ) included 116 patients (median 717 days; range 0\u20132204); 75 (64.4%) remained at endpoint. Ustekinumab (UST) was given to 62 patients (median 660 days; range 50\u20131399); 51 (83.6%) remained at endpoint. Some patients were exposed to multiple biologicals, contributing to smaller numbers for newer drugs. When evaluated as a first-line biological, UST (median 787 days) and VDZ (median 756.5 days) had the shortest durations, while TNF-\u03b1 blockers (ADA, IFX) showed the greatest resistance as first-line therapy. Conclusions: Most patients stayed on their initial therapy after induction and at 1 year. These findings support the sustained use of established biological therapies as cost-effective, steroid-sparing options even after IL-23 approval and may inform patient counseling and long-term pharmacoeconomic considerations.<\/jats:p>","DOI":"10.3390\/jcm14248918","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T12:13:03Z","timestamp":1765973583000},"page":"8918","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug Persistence of Patients with Inflammatory Bowel Disease Under Biological Treatment in the Pre IL-23 Era in a Tertiary Referral Center in Germany"],"prefix":"10.3390","volume":"14","author":[{"given":"Karima","family":"Farrag","sequence":"first","affiliation":[{"name":"Medical Clinic 1, University Hospital, Goethe University Frankfurt, 60590 Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Grimm","sequence":"additional","affiliation":[{"name":"Medical Clinic 1, University Hospital, Goethe University Frankfurt, 60590 Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iulia","family":"Dahmer","sequence":"additional","affiliation":[{"name":"Institute of Biostatistics and Mathematical Modelling, Goethe University Frankfurt, 60590 Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Stratmann","sequence":"additional","affiliation":[{"name":"Medical Clinic 1, University Hospital, Goethe University Frankfurt, 60590 Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antje","family":"Dienethal","sequence":"additional","affiliation":[{"name":"Medical Clinic 1, University Hospital, Goethe University Frankfurt, 60590 Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin","family":"Sprinzl","sequence":"additional","affiliation":[{"name":"Medical Clinic 1, University Hospital, Goethe University Frankfurt, 60590 Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4201-0315","authenticated-orcid":false,"given":"Raul","family":"Lande","sequence":"additional","affiliation":[{"name":"Medical Clinic 1, University Hospital, Goethe University Frankfurt, 60590 Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[{"name":"Medical Clinic 1, University Hospital, Goethe University Frankfurt, 60590 Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Blumenstein","sequence":"additional","affiliation":[{"name":"Medical Clinic 1, University Hospital, Goethe University Frankfurt, 60590 Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alica","family":"Kubesch","sequence":"additional","affiliation":[{"name":"Medical Clinic 1, University Hospital, Goethe University Frankfurt, 60590 Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: The ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease. Crohn\u2019s Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: The CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn\u2019s disease: Results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/gut.2010.221127","article-title":"Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: Results of a randomised controlled trial","volume":"60","author":"Reinisch","year":"2011","journal-title":"Gut"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: The CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/apt.13291","article-title":"Randomised clinical trial: A placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis","volume":"42","author":"Rutgeerts","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1080\/00365521.2017.1304987","article-title":"Long-term effectiveness of vedolizumab in inflammatory bowel disease: A national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)","volume":"52","author":"Eriksson","year":"2017","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1097\/MIB.0000000000000561","article-title":"Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort","volume":"21","author":"Shelton","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/ecco-jcc\/jjv226","article-title":"Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice","volume":"10","author":"Vivio","year":"2016","journal-title":"J. Crohns Colitis"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as Induction and Maintenance Therapy for Crohn\u2019s Disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1111\/jgh.14584","article-title":"Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients","volume":"34","author":"Verstockt","year":"2019","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.crohns.2010.04.004","article-title":"Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects","volume":"4","author":"Allez","year":"2010","journal-title":"J. Crohns Colitis"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.autrev.2013.06.002","article-title":"Optimizing anti-TNF treatments in inflammatory bowel disease","volume":"13","author":"Kopylov","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2036.2011.04679.x","article-title":"Review article: Causative factors and the clinical management of patients with Crohn\u2019s disease who lose response to anti-TNF-\u03b1 therapy","volume":"34","author":"Danese","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00054725-200002000-00002","article-title":"A simple classification of Crohn\u2019s disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998","volume":"6","author":"Gasche","year":"2000","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5A","DOI":"10.1155\/2005\/269076","article-title":"Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology","volume":"19","author":"Silverberg","year":"2005","journal-title":"Can. J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/gut.2010.224154","article-title":"Guidelines for the management of inflammatory bowel disease in adults","volume":"60","author":"Mowat","year":"2011","journal-title":"Gut"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.cgh.2012.02.004","article-title":"Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population","volume":"10","author":"Ha","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/apt.17616","article-title":"Real-world effectiveness of vedolizumab compared to anti-TNF agents in biologic-na\u00efve patients with ulcerative colitis: A two-year propensity-score-adjusted analysis from the prospective, observational VEDOIBD-study","volume":"58","author":"Bokemeyer","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/ibd\/izad138","article-title":"Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naive Crohn\u2019s Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study","volume":"30","author":"Bokemeyer","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/ibd\/izab257","article-title":"Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD","volume":"28","author":"Moens","year":"2022","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/ibd\/izz001","article-title":"Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy","volume":"25","author":"Chen","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/apt.16193","article-title":"Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: Results from nationwide Swedish registers","volume":"53","author":"Rundquist","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cgh.2020.10.003","article-title":"Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis","volume":"20","author":"Lukin","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1097\/MEG.0000000000001831","article-title":"Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn\u2019s disease cohort","volume":"32","author":"Ilus","year":"2020","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/ueg2.12275","article-title":"Ustekinumab treatment in ulcerative colitis: Real-world data from the Swedish inflammatory bowel disease quality register","volume":"10","author":"Thunberg","year":"2022","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1007\/s12325-024-02942-6","article-title":"Real-World Treatment Persistence Among Advanced Therapy-Naive or -Experienced Patients with Ulcerative Colitis Initiated on Ustekinumab or Adalimumab","volume":"41","author":"Zhdanava","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"i1927","DOI":"10.1093\/ecco-jcc\/jjae190.1219","article-title":"P1045 Treat-smart study: Leveraging individual inflammatory markers for personalized therapy in patients with IBD","volume":"19","author":"Medhat","year":"2025","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10238-025-01558-6","article-title":"Biosimilars versus biological therapy in inflammatory bowel disease: Challenges and targeting strategies using drug delivery systems","volume":"25","author":"Aljabri","year":"2025","journal-title":"Clin. Exp. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/24\/8918\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T12:23:51Z","timestamp":1765974231000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/24\/8918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":34,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["jcm14248918"],"URL":"https:\/\/doi.org\/10.3390\/jcm14248918","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]}}}